Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Uniqure N.V.. (9/27/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences in October". Lexington, MA & Amsterdam.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation Uniqure N.V. (Nasdaq: QURE)
  Group Uniqure (Group)
  Organisation 2 Cantor Fitzgerald (Group)
Products Product Cantor Global Healthcare Conference 2019 New York
  Product 2 Cell & Gene Meeting on the Mesa 2019 Carlsbad
Persons Person Kapusta, Matthew (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew Orthopaedics)
  Person 2 Garen, Jonathan (Uniqure 201607– CBO before Syros Pharmaceuticals + Actavis + Forest Labs + Pharmacia Corp)
     


uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in October:


2019 Cantor Global Healthcare Conference, October 2 – 4, New York City.

° Matt Kapusta, chief executive officer at uniQure, will present a corporate update on Wednesday, October 2, at 9:30 a.m. ET. The live webcast of the corporate update can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.


2019 Cell & Gene Meeting on the Mesa, October 2 – 4, Carlsbad, California.

° Jonathan Garen, chief business officer at uniQure, will participate in a panel discussion "Cell and Gene Therapy for Neurological Product Indications" on Wednesday October 2, at 4:00 p.m. PT.
° Mr. Garen also will present a corporate update on Wednesday, October 2, at 2:45 p.m. PT.


National Hemophilia Foundation 71st Bleeding Disorders Conference, October 3 – 5, Anaheim, California.

° uniQure will deliver the following presentations during the conference:

• Title: No Evidence of Germline Transmission of Vector DNA Following Intravenous Administration of AAV5-hFIX to Male Mice
Abstract number: CRA21
Presentation date: Friday, October 4
Presentation time: 5:15 – 6:15 p.m. PT

• Title: AMT-061 (AAV5-Padua hFIX variant) an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Follow-up up to 9 Months in a Phase 2b trial
Abstract number: QOL29
Presentation date: Friday, October 4
Presentation time: 5:15 – 6:15 p.m. PT

• Title: An Evaluation of Health Utility and Quality-of-Life in Hemophilia: A Systematic Literature Review
Presentation date: Friday, October 4
Presentation time: 5:15 – 6:15 p.m. PT


European Huntington Association 2019 Conference, October 4 – 6, Bucharest, Romania.

° Melvin Evers, Ph.D., associate director research at uniQure, will be presenting on the Company’s gene therapy candidate AMT-130 for Huntington’s disease on Sunday October 6, at 10:30 a.m. CET.
° Dr. Evers will also participate in a panel discussion at the conclusion of the presentation session "Drug Trials in Huntington’s Disease: What is Happening Right Now?" at 11:20 a.m. CET.


Chardan 3rd Annual Genetic Medicines Conference, October 7 – 8, New York City

° Matt Kapusta will participate in a fireside chat with research analyst Gbola Amusa on Tuesday, October 8, at 11:00 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.


European Society for Gene and Cell Therapy 2019 Collaborative Congress, October 22 – 25, Barcelona, Spain.

° uniQure will deliver the following presentations during the conference:

• Title: A Novel AAV-Based miQURE Gene Therapy for Spinocerebellar Ataxia Type 3
Abstract number: P247
Presentation date: Wednesday, October 23
Presentation time: 1:00 – 2:30 p.m. CET

• Title: Stem Cell Derived Brain Organoids, a Promising Model to Study Adeno Associated Viruses for CNS Gene Therapy
Abstract number: P381
Presentation date: Wednesday, October 23
Presentation time: 1:00 – 2:30 p.m. CET

• Title: Prevalence and Affinity/Avidity Assessment of Pre-Existing NABs Against AAV2, 5 and 8 Analyzed in the Serum of 300 Healthy Donors
Abstract number: P336
Presentation date: Thursday, October 24
Presentation time: 1:00 – 2:30 p.m. CET


About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com


uniQure Contacts:

FOR INVESTORS: FOR MEDIA:

Maria E. Cantor Eva M. Mulder Tom Malone
Direct: 339-970-7536 Direct: +31 20 240 6103 Direct: 339-970-7558

   
Record changed: 2019-11-03

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Uniqure (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top